DiaMedica Therapeutics (NASDAQ:DMAC) Stock Rating Lowered by Zacks Investment Research

Zacks Investment Research downgraded shares of DiaMedica Therapeutics (NASDAQ:DMAC) from a hold rating to a sell rating in a research note published on Friday morning, Zacks.com reports.

According to Zacks, “DiaMedica Therapeutics Inc. is a biopharmaceutical company. It engages in the development of novel recombinant proteins and monoclonal antibodies. The companys lead product principally consists DM199, a recombinant human tissue kallikrein-1 protein. It operates primarily in the United States and Canada. DiaMedica Therapeutics Inc. is headquartered in Minneapolis, Minnesota. “

Shares of NASDAQ DMAC traded up $0.36 during midday trading on Friday, reaching $3.74. 117,773 shares of the stock were exchanged, compared to its average volume of 36,537. DiaMedica Therapeutics has a twelve month low of $1.70 and a twelve month high of $5.93. The firm has a 50-day simple moving average of $3.14 and a two-hundred day simple moving average of $3.16. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.97 and a quick ratio of 8.97.

DiaMedica Therapeutics (NASDAQ:DMAC) last issued its quarterly earnings data on Wednesday, November 13th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). Analysts expect that DiaMedica Therapeutics will post -0.93 EPS for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Worth Venture Partners LLC grew its stake in shares of DiaMedica Therapeutics by 10.6% during the 2nd quarter. Worth Venture Partners LLC now owns 132,514 shares of the company’s stock worth $657,000 after purchasing an additional 12,651 shares during the period. Millennium Management LLC grew its stake in shares of DiaMedica Therapeutics by 54.6% during the 3rd quarter. Millennium Management LLC now owns 70,919 shares of the company’s stock worth $145,000 after purchasing an additional 25,037 shares during the period. Vanguard Group Inc. acquired a new stake in shares of DiaMedica Therapeutics during the 2nd quarter worth approximately $170,000. BlackRock Inc. grew its stake in shares of DiaMedica Therapeutics by 159.7% during the 2nd quarter. BlackRock Inc. now owns 27,075 shares of the company’s stock worth $134,000 after purchasing an additional 16,651 shares during the period. Finally, Commonwealth Equity Services LLC acquired a new stake in shares of DiaMedica Therapeutics during the 3rd quarter worth approximately $27,000. 8.01% of the stock is currently owned by institutional investors and hedge funds.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications.

Featured Article: How does inflation affect different investments?

Get a free copy of the Zacks research report on DiaMedica Therapeutics (DMAC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for DiaMedica Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaMedica Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit